AbbVie Q4 Revenues Rise 10% to $16.61B as Immunology Sales Jump 18.3%
AbbVie reported fourth-quarter net revenues of $16.61 billion, up 10% year-on-year driven by an 18.3% rise in immunology sales to $8.63 billion, delivering adjusted EPS of $1.02. Full-year net revenues reached $61.16 billion (+8.6%), and it forecasts 2026 EPS of $14.37 to $14.57 after acquiring a device facility in Tempe.
1. Fourth-Quarter Financial Results
AbbVie delivered Q4 net revenues of $16.61 billion, marking a 10% year-over-year increase. Immunology portfolio sales rose 18.3% to $8.63 billion, and diluted EPS in the quarter was $1.02.
2. Full-Year Performance and Guidance
Full-year net revenues totaled $61.16 billion, up 8.6% from the prior year, driven by a 14% increase in the immunology business. Adjusted diluted EPS for 2025 was $10.00, and AbbVie forecasts 2026 EPS between $14.37 and $14.57.
3. Strategic Acquisition
During the quarter, AbbVie agreed to acquire a device manufacturing facility and related intellectual property in Tempe, aiming to bolster development of next-generation immunology and neuroscience therapies as part of its diversified growth platform.